Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma – Fierce Biotech
… chronic obstructive pulmonary disease (COPD). Gilead isn’t sharing what specific areas it will hone in on—which is not unusual given how early …
… chronic obstructive pulmonary disease (COPD). Gilead isn’t sharing what specific areas it will hone in on—which is not unusual given how early …
